Amgen Licenses Astellas-Partnered AMG 337 To NantPharma
This article was originally published in Scrip
Executive Summary
NantPharma LLC, a subsidiary of Patrick Soon-Shiong's NantWorks LLC empire, licensed AMG 337 outside of Japan, Russia and other central Asian countries from Amgen Inc., which previously partnered with Astellas Pharma Inc. to develop the cancer drug and four other compounds in certain Asia territories.
You may also be interested in...
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.